Contraindication of Tranexamic Acid in Patients on Warfarin for Stroke Prevention

Warfarin Therapy and Stroke‑Prevention Context

Warfarin produces a systemic anticoagulant state by inhibiting vitamin K‑dependent clotting factors, with target INR 2.0–3.0 for stroke prevention in atrial fibrillation. 1
Patients receiving warfarin for stroke prevention have already experienced a stroke/TIA or have atrial fibrillation with a CHADS₂ score ≥ 2, indicating high thromboembolic risk. 1
Direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban) are now preferred over warfarin for non‑valvular atrial fibrillation because they provide comparable efficacy with lower bleeding rates. 1

In the event of warfarin‑related intracranial bleeding, immediate reversal with prothrombin complex concentrate (or fresh frozen plasma) plus vitamin K is mandatory; antifibrinolytic agents such as tranexamic acid are not recommended. 2
The American Heart Association/American Stroke Association (AHA/ASA) guidelines advise discontinuing all antithrombotic agents for a minimum of 1–2 weeks after an intracranial hemorrhage in patients on warfarin. 2
Protamine sulfate is the specific antidote for heparin‑associated hemorrhage; the required dose depends on the interval since heparin cessation. 2
Between 30 % and 40 % of intracranial hemorrhages enlarge within the first 12–36 hours, and an elevated INR markedly increases this expansion risk. 3
Lobar hemorrhages—often reflecting cerebral amyloid angiopathy—carry a higher risk of recurrence and may contraindicate the resumption of anticoagulation. 3

For patients with relatively low ischemic‑stroke risk (e.g., atrial fibrillation without prior stroke) but high hemorrhagic risk (e.g., elderly with lobar ICH), antiplatelet therapy may be considered as an alternative to restarting warfarin. 2
In individuals with very high thromboembolic risk (mechanical heart valves, recent stroke), warfarin may be re‑initiated 7–10 days after hemorrhage onset, but never concurrently with tranexamic acid. 2
When a hemorrhagic transformation of an ischemic stroke is small and asymptomatic, continuation of anticoagulation can be reasonable. 4

If a patient on warfarin sustains major traumatic hemorrhage, any use of tranexamic acid must be accompanied by simultaneous warfarin reversal using the measures outlined above (PCC/FFP + vitamin K). 2

For elderly patients with prior stroke, dose should be reduced according to serum creatinine:
- Creatinine 1.36–2.83 mg/dL → 10 mg/kg twice daily
- Creatinine 2.83–5.66 mg/dL → 10 mg/kg once daily
- Creatinine > 5.66 mg/dL → 10 mg/kg every 48 hours – adjusted to preserve renal function. 5

Subarachnoid hemorrhage and active intravascular clotting are absolute contraindications for tranexamic acid in this population. 5

Tranexamic acid is beneficial only if given within 90 minutes of injury; mortality is reduced (adjusted risk ratio 0.64, 95 % CI 0.50–0.82).
Recommended regimen: 1 g IV bolus followed by 1 g infused over 8 hours. 6, 7, 8, 9

Treatment must be initiated within 3 hours of head injury; delayed administration (>3 h) increases risk of death from hemorrhage (RR 1.44, 95 % CI 1.12–1.84).
Same dosing protocol (1 g bolus + 1 g over 8 h) is used. 6, 7, 8, 9

Giving tranexamic acid after 90 minutes for trauma or after 3 hours for TBI provides no mortality benefit and may cause harm (elevated death risk). 6, 7, 8, 9

Limit infusion to the standard 8‑hour protocol; avoid prolonged courses (>1 day) to reduce thrombotic risk. (Evidence from cited trials supports this precaution.)

All facts are derived from peer‑reviewed studies and guideline‑level recommendations; citation IDs are provided for reference.